Medifast Earnings Call Transcripts
Fiscal Year 2026
-
Sequential revenue growth returned for the first time in three years, driven by a 19% year-over-year increase in coach productivity and strong referral activity, despite a 34% revenue decline and ongoing disruption from GLP-1 medications. Profitability improvements are targeted for Q4 2026, with a new product launch and cost savings expected to support future growth.
Fiscal Year 2025
-
Q4 2025 saw revenue drop 36.9% year-over-year due to a smaller coach base, but coach productivity rose 6%, marking the first positive trend since 2022. The company is transitioning to a metabolic health focus, expects new product launches in late 2026, and targets profitability improvements starting Q4 2026.
-
Q3 revenue and EPS were at the high end of guidance, but revenue fell 36% year-over-year due to a sharp decline in active coaches. The company is shifting focus to metabolic health, launching new products in 2026, and expects stabilization in coach productivity and revenue per coach in the coming quarters.
-
Q2 2025 revenue and EPS exceeded guidance despite a 37% revenue drop and a 33% decline in active coaches. New pricing and incentive programs were launched, and the company remains debt-free with strong cash reserves. GLP-1 trends and metabolic health remain central to strategy.
-
Q1 2025 revenue and EPS were within guidance, but revenue fell 33.8% year-over-year due to fewer active coaches. New coach cohorts and product lines like Ascend are showing promise, with improved productivity and customer acquisition. Cash position remains strong with no debt.
Fiscal Year 2024
-
Revenue and net income declined sharply year-over-year, but cost savings and new product launches like OPTAVIA ASCEND helped stabilize key metrics. Coach productivity is showing signs of improvement, and the company maintains a strong cash position with no debt.
-
Q3 revenue and net income declined sharply year-over-year due to GLP-1 competition and lower coach productivity. Strategic transformation is underway, with new product launches and enhanced technology planned for early 2025. Cash position remains strong, and no external financing is expected in 2025.
-
Q2 2024 revenue declined 43% year-over-year amid competitive and macroeconomic pressures, but gross margin improved. Strategic investments in GLP-1 support products, digital tools, and marketing are expected to drive growth from late 2024 into 2025.